<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136850</url>
  </required_header>
  <id_info>
    <org_study_id>70270</org_study_id>
    <nct_id>NCT01136850</nct_id>
  </id_info>
  <brief_title>Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea</brief_title>
  <acronym>IPTp in PNG</acronym>
  <official_title>Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Papua New Guinea Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter and Eliza Hall Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Melbourne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether repeated courses of
      sulphadoxine-pyrimethamine (SP) in combination with azithromycin given at Antenatal Clinic,
      leads to lower rates of low birth weight deliveries (&lt;2.5 kg) among Papua New Guinean women,
      than the current standard treatment of SP and chloroquine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women delivering low birth weight babies, &lt;2500 g</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of P falciparum at delivery in peripheral, placental and cord blood films and on placental histology</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maternal hemoglobin concentration at delivery, and proportion of women anaemic (Hb &lt; 11 g/dl).</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence (at enrolment, second treatment, and delivery) and consequences (maternal haemoglobin, birth weight and placental pathology) of P. vivax infection in pregnancy</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>From enrolment at 14-26 weeks gestation, until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic malaria during pregnancy</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>From enrolment at 14-26 weeks until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women carrying azithromycin-sensitive sexually transmitted infections at second treatment visit (28-34 weeks).</measure>
    <time_frame>28-34 week gestation study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, including severe adverse events (SAEs), and AEs possibly or probably associated with study medications</measure>
    <time_frame>14-26 weeks</time_frame>
    <description>From enrolment at 14-26 weeks gestation until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug resistance markers in parasites infecting women in late pregnancy, particularly in the P falciparum and P vivax dihydrofolate reductase and dihydropteroate synthase enzymes, associated with SP resistance</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and antibiotic sensitivity patterns of S. pneumoniae in nasopharyngeal swabs collected at delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal, perinatal and infant mortality rates</measure>
    <time_frame>Mothers; up to 32 weeks, from enrolment at 14-26 weeks gestation, until delivery. Pernatal: 16 weeks, from 28 weeks gestation to 4 weeks of age. Infant: from live birth to 1 year of age</time_frame>
    <description>maternal mortality is during pregnancy and until 6 weeks post partum. Perinatal mortality is from 28 weeks gestation until 6 weeks postpartum. Infant mortality is from irth to 12 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of IPTp on development of immunity to malaria in pregnancy</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of parasites infecting pregnant women</measure>
    <time_frame>Up to 26 weeks, from 14-26 weeks gestation until delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2793</enrollment>
  <condition>Malaria in Pregnancy</condition>
  <condition>Sexually Transmitted Infections</condition>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>SP, chloroquine treatment; bed net</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 x SP plus azithromycin; bed nets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chloroquine, sulphadoxine pyrimethamine, LLIN</intervention_name>
    <description>&gt; 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
&lt; 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
Given at enrolment, 14-26 weeks gestation, by mouth.</description>
    <arm_group_label>SP, chloroquine treatment; bed net</arm_group_label>
    <other_name>sulfadoxine-pyrimethamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin, sulphadoxine pyrimethamine, LLIN</intervention_name>
    <description>sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).
Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.</description>
    <arm_group_label>3 x SP plus azithromycin; bed nets</arm_group_label>
    <other_name>Zithromax</other_name>
    <other_name>sulfadoxine-pyrimethamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant

          -  14-26 weeks'gestation

          -  permanent resident of study area

          -  exclusive use of study health facilities for primary health care

          -  Age is between 16 and 49 years

        Exclusion Criteria:

          -  Known chronic illness, e.g. TB, diabetes, renal failure

          -  Severe anaemia requiring hospitalisation (Hb &lt; 6 g/dl accompanied by symptoms
             requiring urgent treatment)

          -  permanent disability, that prevents or impedes study participation and/or
             comprehension

          -  Known multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Rogerson, FRACP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papua New Guinea Institute of Medical Research</name>
      <address>
        <city>Madang</city>
        <state>Madang Province</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <link>
    <url>http://mip-consortium.org</url>
    <description>home page of umbrella organisation coordinating this and other trials on malaria in pregnancy</description>
  </link>
  <link>
    <url>http://www.medrmhwh.unimelb.edu.au/</url>
    <description>home page of Department of Central contact person, Dr Rogerson</description>
  </link>
  <link>
    <url>http://www.pngimr.org.pg</url>
    <description>home page of Papua New Guinea Institute of Medical Research</description>
  </link>
  <reference>
    <citation>Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):28-35. Review.</citation>
    <PMID>11425175</PMID>
  </reference>
  <reference>
    <citation>Guyatt HL, Snow RW. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):36-44. Review.</citation>
    <PMID>11425176</PMID>
  </reference>
  <reference>
    <citation>Brabin B, Piper C. Anaemia- and malaria-attributable low birthweight in two populations in Papua New Guinea. Ann Hum Biol. 1997 Nov-Dec;24(6):547-55.</citation>
    <PMID>9395740</PMID>
  </reference>
  <reference>
    <citation>Benet A, Khong TY, Ura A, Samen R, Lorry K, Mellombo M, Tavul L, Baea K, Rogerson SJ, Cortés A. Placental malaria in women with South-East Asian ovalocytosis. Am J Trop Med Hyg. 2006 Oct;75(4):597-604.</citation>
    <PMID>17038679</PMID>
  </reference>
  <reference>
    <citation>Allen SJ, Raiko A, O'Donnell A, Alexander ND, Clegg JB. Causes of preterm delivery and intrauterine growth retardation in a malaria endemic region of Papua New Guinea. Arch Dis Child Fetal Neonatal Ed. 1998 Sep;79(2):F135-40.</citation>
    <PMID>9828741</PMID>
  </reference>
  <reference>
    <citation>Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994 Nov;51(5):515-22.</citation>
    <PMID>7985742</PMID>
  </reference>
  <reference>
    <citation>Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998 Nov;59(5):813-22.</citation>
    <PMID>9840604</PMID>
  </reference>
  <reference>
    <citation>Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol. 1998 Mar;92(2):141-50.</citation>
    <PMID>9625909</PMID>
  </reference>
  <reference>
    <citation>Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999 Feb 20;353(9153):632-6.</citation>
    <PMID>10030329</PMID>
  </reference>
  <reference>
    <citation>Casey GJ, Ginny M, Uranoli M, Mueller I, Reeder JC, Genton B, Cowman AF. Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Am J Trop Med Hyg. 2004 Mar;70(3):251-5.</citation>
    <PMID>15031512</PMID>
  </reference>
  <reference>
    <citation>ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007 Jun 20;297(23):2603-16. Review.</citation>
    <PMID>17579229</PMID>
  </reference>
  <reference>
    <citation>Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Alker AP, Kwiek JJ, Meshnick SR. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One. 2007 Nov 14;2(11):e1166.</citation>
    <PMID>18000538</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>April 20, 2013</last_update_submitted>
  <last_update_submitted_qc>April 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Melbourne</investigator_affiliation>
    <investigator_full_name>Stephen Rogerson</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Plasmodium vivax</keyword>
  <keyword>azithromycin</keyword>
  <keyword>sulphadoxine pyrimethamine</keyword>
  <keyword>low birth weight</keyword>
  <keyword>haemoglobin</keyword>
  <keyword>Chlamydia trachomatis</keyword>
  <keyword>Neisseria gonorrhoeae</keyword>
  <keyword>Treponema pallidum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

